“Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose” (2022) Clinics, 78, p. 100150. doi:10.1016/j.clinsp.2022.100150.